TCRX – tscan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TScan Therapeutics (TCRX) had its price target raised by Wedbush from $4.00 to $5.00. They now have an "outperform" rating on the stock.
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 [Yahoo! Finance]
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
Form S-8 TScan Therapeutics, Inc.
Form 10-K TScan Therapeutics, Inc. For: Dec 31
Form 8-K TScan Therapeutics, Inc. For: Mar 04
Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: Amello Jason
Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: MacBeath Gavin
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.